Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAXOPS)

• Drug Name: viral macrophage inflammatory protein-II Drug Info
• Synonyms: CFLTKRGRQVC; vMIP-II; Viral macrophage inflammatory protein-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 486830
  TTD Drug ID: DMAXOPS

Molecule-Related Drug Atlas

Drug(s) Targeting C-C chemokine receptor type 8 (CCR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GS-1811	DMCEMC6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
CCX-832	DMD8QHV	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[5]
ZK 756326	DMP089G	Discovery agent	N.A.	Investigative	[6]
I-309	DM7QE51	Discovery agent	N.A.	Investigative	[7]
N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide	DMQS9OH	Discovery agent	N.A.	Investigative	[8]
N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide	DM74KHG	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting C-C chemokine receptor (CCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-481,715	DMZT7C1	Discovery agent	N.A.	Investigative	[9]
UCB35625	DMQB8C3	Discovery agent	N.A.	Investigative	[10]
PMID12614873C2b-1	DMXFY4P	Discovery agent	N.A.	Investigative	[11]
VT-224	DMB7I0A	Inflammation	1A00-CA43.1	Investigative	[12]

Drug(s) Targeting CCR5 messenger RNA (CCR5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Maraviroc	DMTL94F	Human immunodeficiency virus infection	1C62	Approved	[13]
DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells	DM0I5LM	Human immunodeficiency virus infection	1C62	Phase 1/2	[14]
SCH-C	DM8J9SF	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[15]

Drug(s) Targeting C-C chemokine receptor type 2 (CCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[16]
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[17]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[18]
CCX-140	DMJ9XCO	Diabetic nephropathy	GB61.Z	Phase 2	[19]
AZD-2423	DMF34UY	Chronic obstructive pulmonary disease	CA22	Phase 2	[20]
CCX872	DMPVAUT	Pancreatic tumour	2C10	Phase 2	[21]
MK-0812	DMRT8K4	Multiple sclerosis	8A40	Phase 2	[22]
Aminoguanidine	DMJQDUC	Diabetic retinopathy	9B71.0	Phase 1	[23]
TAK-202	DMVYEFZ	Melanoma	2C30	Phase 1	[24]
OPL-CCL2-LPM	DM3HOUX	Arthritis	FA20	Phase 1	[25]

Drug(s) Targeting C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Plerixafor	DMCJN1P	Non-hodgkin lymphoma	2B33.5	Approved	[26]
Motixafortide	DMW34B1	Multiple myeloma	2A83	Approved	[27]
Ulocuplumab	DM6PMNR	Multiple myeloma	2A83	Phase 3	[28]
Balixafortide	DMUOFAC	Metastatic breast cancer	2C6Y	Phase 3	[29]
AMD-070	DMVOY6B	Whim syndrome	4A00.Y	Phase 3	[30]
TG-0054	DM2ZLWH	Macular degeneration	9B78.3	Phase 2	[31]
POL-6326	DM4OT29	Human immunodeficiency virus infection	1C62	Phase 2	[32]
CTCE-9908	DM95XR8	Sarcoma	2A60-2C35	Phase 1/2	[33]
USL311	DM6HPEC	Recurring respiratory infection	CA07-CA45	Phase 1/2	[24]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor (CCR)	TT8KLPT	NOUNIPROTAC	Antagonist	[2]
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Antagonist	[2]
C-C chemokine receptor type 8 (CCR8)	TTE836A	CCR8_HUMAN	Antagonist	[3]
C-X-C chemokine receptor type 4 (CXCR4)	TTBID49	CXCR4_HUMAN	Antagonist	[2]
CCR5 messenger RNA (CCR5 mRNA)	TTJIH8Q	CCR5_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 768).
• [2] A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.
• [3] HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74.
• [4] Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022 Nov 4;11(1):2141007.
• [5] Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877.
• [6] Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16.
• [7] The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51.
• [8] Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.
• [9] CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem. 2003 Oct 17;278(42):40473-80.
• [10] A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem. 2000 Aug 25;275(34):25985-92.
• [11] Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem. 2003 Mar 20;11(6):875-84.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 67).
• [13] Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
• [14] Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980.
• [15] Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [18] A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
• [19] Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
• [20] CA patent application no. 841416, Method of selecting therapeutic indications.
• [21] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
• [22] Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
• [23] Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
• [26] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [27] The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
• [28] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [29] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [30] Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
• [31] CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
• [32] CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
• [33] A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
• [34] Clinical pipeline report, company report or official report of GlycoMimetics.